Health Blueprint

Back to Longevity News

News summary

Immorta Bio doses first patient with senolytic immunotherapy in Mexico

Source: Longevity Docs News • Published: 05 Nov 2026, 00:00

Summarized by Masters of Longevity from Longevity Docs News.

Company reports one unregistered dosing of a peptide immunotherapy in an advanced cancer patient.

Immorta Bio doses first patient with senolytic immunotherapy in Mexico
Key Takeaways
  • One unregistered human dose was administered by Immorta Bio.
  • Mouse studies funded by the company showed tumor shrinkage.
  • Safety and efficacy in humans have not been established.
Read the full article at Longevity Docs News ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickGrowth Hormone Receptor Deletion Extends Mouse LifespanStudy summary: researchers switched off the growth hormone receptor in middle-aged mice and followed survival and physical function.